Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Clinical Anatomy and Physiology

Journal homepage: https://www.ijcap.org/

Review Article

Intracellular trafficking in pathophysiological conditions

Anuradha Paria[1], Rojina Khatun[1], Sudeshna Sengupta[1], Malavika Bhattacharya[1]*

[1]Dept. of Biotechnology, Techno India University, West Bengal, Kolkata, India.

Abstract

Intracellular trafficking is a highly complex network process by which protein and lipid movement occurs within the cell. This mechanism is essential for controlling cellular processes, maintaining metabolic homeostasis, and ensuring membrane integrity. Disruptions in trafficking can cause cellular malfunction and contribute to the development of a variety of pathological diseases. This paper tries to outline current knowledge of intracellular trafficking and its relationship to illness. The paper focuses on how changes in trafficking processes can result in a variety of pathological conditions. For example, neuroinflammation is a major component of Alzheimer's disease, and genetic variations such as TREM2 have been related to the condition. The endoplasmic reticulum (ER) also plays an important role in protein production, notably the creation of Na, K-ATPases. When ER trafficking is disturbed, protein misfolding occurs, which increases ER stress and speeds up disease development. Furthermore, mitochondrial dysfunction is a major contributor to neurodegenerative disorders. Impaired mitochondrial transport and energy generation worsen cellular damage and contribute to the development of these diseases. This paper provides readers with a better knowledge of how disruption in intracellular trafficking pathways might contribute to the beginning and progression of many illnesses, as well as possible therapeutic targets for intervention.

Keywords: Trafficking, Neuroinflammation, Alzheimer's, ER stress, Mitochondria, Therapy.

Received: 09-05-2025; **Accepted:** 12-06-2025; **Available Online**: 05-07-2025

Introduction

The anatomical existence of distinct organelles was the foundation for the initial definition of cellular compartmentalization. Lately, the concept has grown to cover the spatial separation of metabolites, big molecules, and biochemical pathways. These pathways connect the structure and jobs of organelles, and all these elements are important to consider over time and space.[1]With today's advanced structural methods (plus all those biochemical computational approaches), people are diving into the world of cell trafficking and related diseases. They're uncovering new mechanisms and genes involved, reaching levels of complexity we hadn't imagined before.[2] Intracellular trafficking is essential for maintaining homeostasis and cellular function, and its disruption is associated with several pathological conditions. Human disorders can result from flaws in trafficking mechanisms that impact cellular function and protein transport.[3] Likewise, in Alzheimer's disease, β-amyloid production can be impacted by disrupted trafficking of proteins such as APP and secretases, which speeds up pathogenesis.[4] Instead of using a one-size-fits-all strategy for managing Alzheimer's disease (AD), precision medicine offers a promising alternative therapeutic approach.[5] Numerous genetic variations and molecular pathways contribute to neuroinflammation, a major pathogenic mechanism that manifests decades before AD onset.[6] Neuroinflammation biomarkers such as TREM2, IL-1β, and TNF-α are being validated to monitor the course of the disease.[7] Impaired intracellular trafficking, especially in dopaminergic neurons, is increasingly associated with early-onset Parkinson's disease (PD).[8] The accumulation of α-synuclein and synaptic dysfunction are caused by defects in membrane trafficking pathways, which may also help misfolded proteins spread.[9] Moreover, autophagy and synaptic vesicle trafficking are both mediated by a large number of PD-related genes, indicating a link between these processes in the pathophysiology of PD.[10] In neuronal development and function, mitochondria are essential

Corresponding author: Malavika Bhattacharya
Email: malavikab@gmail.com

http://doi.org/10.18231/j.ijcap.2025.011

components that impact several processes, including calcium regulation, axon branching, and synaptic function.[11]These organelles are active as well and can move within the cytoplasm via fusion and fission along the microtubules and are therefore important for the distribution within neurons.[12] Neurodegenerative illnesses such as Parkinson's disease and compromised neuronal development have been connected to mitochondrial dysfunction.[13] G protein-coupled receptors (GPCRs), studied as β-adrenergic receptors (βARs), are crucial for cellular signaling. Also, recent research suggests that βAR trafficking can also help to relocate signaling machinery to intracellular compartments.[14] The dysregulation of lymphocyte trafficking has been recognized to have major functional and clinical relevance. The microenvironment in hematologic malignancies, especially Hodgkin's lymphoma, is enriched for specific phenotypes and functions of T-cells.[15] The fine stores of the cytoskeleton and molecular busy work together, coordinating the process of T-cell movement, activation, and functional responses. Many molecules in a wide variety exist to regulate this interplay, such as regulators of polarity and linkers between the membrane and cytoskeleton, with an essential role in T-cell migration, immunological synapse formation, and effector functions.[16] Mucins, high-molecular-weight glycoproteins that serve to perform a wide array of biological functions.[17] are commonly expressed aberrantly during pathological states. Aberrant expression and glycosylation of glycoconjugates are linked to the pathogenesis of malignant diseases, which provide several unique opportunities for clinical use.[18] Of these, MUC16 is the most abundant and largest of the mucins and has emerged as a potential biomarker or therapeutic target in cancers.[19] Abnormal mucin trafficking and subcellular localization under pathological conditions influence cell signaling, leading to the facilitation of cancer advancement.[20] Rab proteins, specifically Rab27 and its isoforms, regulate vesicular trafficking, an essential cellular function[21] Because they interact with multiple effector molecules, Rab27 GTPases play a variety of roles in different cell types, regulating exocytosis, endocytosis, and.[22]

1. Various Pathophysiological Conditions

2.1. Neuroinflammation and cell mediators: Unraveling inflammatory pathways in Alzheimer's disease.

Neuroinflammation is a first-line immune response of the nervous system itself that involves microglia, astrocytes, cytokines, and chemokines. These elements play a key role in the early stages. Stages of Alzheimer's disease (AD) development.[23] Astrocytes play a crucial role in forming new synapses by supporting the growth of axons and dendritic spines. They also help maintain the strength and stability of synaptic connections.[24] Microglial cells are crucial for monitoring the presynaptic environment and shaping neural connections as illustrated in **Figure 1**.

They help refine axons and dendritic terminals through protein breakdown and phagocytosis.[25] As part of initiating an immune response, microglia express a large variety of receptors recognizing exogenous or endogenous CNS insults. In addition, microglial cells promote the protection of the brain by phagocytic clearance stimulation and support to maintain cerebral homeostasis. It also enables tissue repair in situations involving loss of homeostasis or during tissue changes, where various dynamic microglial mechanisms can be activated, leading to the activation of the state of microglia.[26] The activated phenotype determines whether microglia can elicit cytotoxic or neuroprotective effects. Experimental AD models show that microglia may contribute to both Aβ accumulation and accumulation around amyloid plaques, likely driven by chemotactic processes.[28] Proinflammatory cytokine production and release, as well as other harmful elements, are increased during AD pathogenesis. Furthermore, microglia's usual phagocytic function is diminished. The spread of the disease within and between brain regions is influenced by microglia, which regulate the release of apoptosis-associated speck-like protein that contains a caspase-recruitment domain (ASC).[29] Finally, reactive microglia release extracellular vesicles, which are made up of microvesicles and exosomes.[30] Microglial cells can control AD pathogenesis by actively interacting with neurons, astrocytes, and oligodendrocytes. Certainly, proinflammatory cytokines released by activated microglial cells cause altered astrocytes. These astrocytes can hasten and exacerbate the death of oligodendrocytes and neurons.[31] Like neurons and oligodendrocytes, but unlike microglia, astrocytes are derived from the neuroectoderm.[32] Each astrocyte interacts with hundreds of neuronal dendrites by wrapping multiple neurons.[33] Cytoplasmic inclusions of non-fibrillar Aβ have been found inside astrocytes in human neuropathological studies of AD brains. These inclusions are thought to represent astrocytes engulfing extracellular Aβ deposits through phagocytosis.[34]



Figure 1: This figure illustrates the multifunctional roles of microglia in the progression of Alzheimer's disease. It highlights how microglia regulate immune responses, perform phagocytosis, and interact with neuronal and glial cells, collectively influencing Aβ accumulation and neurodegeneration.

2.2 Impaired intracellular trafficking: A key hallmark of early parkinson's disease.

Parkinson's disease (PD) is a prevalent neurodegenerative disease that is characterized by a subtle decline in motor control. It is frequently linked to mood, sleep, and cognitive issues.[35] PD affects more than 1% of adults over 65.[36] Transport along microtubules is necessary for the movement of vesicles and organelles such as ribosomes, mitochondria, and synaptic vesicles through the cell.[37] Because human SNc DA neurons require cellular trafficking machinery far more than other neuron types, SNc DA neurons are disproportionately affected by any impairment of cellular trafficking. Since cellular trafficking relies on the hydrolysis of ATP to fuel the major motor proteins, kinesin and dynein, 1 molecule of ATP is needed for every 8 nm of cellular transit.[38] The existence of α-synuclein within Lewy bodies, which are hereditary instances of PD due to genetic mutation producing α-synuclein (SNCA), is one of several different lines of research that have linked the protein α-synuclein to the pathophysiology of PD.[39] The synuclein family includes three proteins: α-, β-, and γ-synuclein. These proteins form α-helices on phospholipids. Combinatorial knockout mice were used in studies to establish functional overlap in the roles of synucleins. Research has shown that the synucleins play a role in dopamine (DA) release, either directly or indirectly. For example, when synucleins are removed, the release of dopamine increases.[40] In DA neurons, the buildup of α-synuclein, especially in its soluble forms, can have damaging effects without forming insoluble aggregates as visualized in **Figure 2**.[41-42] The early signs of PD mainly involve reduced dopamine (DA) release and damage to synapses,[43] both of which are linked to the natural location of α-synuclein, which is primarily at the presynaptic terminal. The bacterial artificial chromosome (BAC) transgenic mouse model of PD illustrates this. It carries the human SNCA gene along with its surrounding regulatory regions and produces human α-synuclein in a physiologically relevant manner that is relevant to both space and time.[44] All of these results point to the dorsal striatum serving as an early warning sign of PD, where disrupted intracellular transport interferes with the regulation of dopamine synapses. Structure and pathogenicity likely interact in this way; the requirement to keep the DA synapse far from the cell body may isolate it to a degree that other neurons do not.[45]



Figure 2: The image presents how disruptions in intracellular trafficking, particularly involving synaptic vesicles and α-synuclein accumulation, contribute to neuronal dysfunction in Parkinson's disease, especially within dopaminergic pathways.

2.3. Mitochondria's effect on neuronal development and disease

Mitochondria, beyond their conventional function in energy production, are essential for the growth and operation of neurons, **Figure 3** illustrates mitochondrial functions in neurons. These dynamic organelles influence neurogenesis, calcium regulation, synaptic function, and axon branching.[46] Mitochondrial dynamics, including fusion and fission, are crucial for developmental and disease processes.[47] Mitochondrial distribution and morphology undergo significant changes during neural differentiation, reflecting the metabolic state of the cells.[48] Mitochondria manage cellular energy levels and participate in various metabolic activities, including biomolecule production and calcium signaling.[49] Their malfunction can lead to a wide range of neurodevelopmental and neurodegenerative disorders.[50]



Figure 3: This figure showcases the vital functions of mitochondria in brain cells, including energy (ATP) production and calcium regulation, underscoring their role in maintaining neuronal activity and health.

Neurons exhibit highly specialized processes within their sub-compartments—dendrites, axons, dendritic spines, and axonal terminals—enabling precise regulation of essential cellular activities. Among these compartmentalized processes is local protein synthesis, which occurs in both axonal and somatodendritic regions as **Figure 4** highlights the distribution of mitochondria in axons and dendrites. This mechanism is crucial for neurite development and repair, synaptic strengthening, and memory formation.[51]



Figure 4: Displayed here is the mitochondrial architecture across neuronal compartments such as axons and dendrites. It illustrates their interaction with the ER, local energy supply at synapses, and involvement in intracellular calcium dynamics.

Mitochondrial morphology in cells is governed by two opposing processes: fission and fusion. These processes are regulated by various proteins, many of which exhibit species-specific characteristics.[52] The balance between mitochondrial fusion and fission dynamics plays a crucial role in shaping mitochondrial morphology, resulting in either more fragmented or elongated forms.[53] These morphological changes are thought to represent an essential aspect of metabolic flexibility, allowing cells to adapt to fluctuating metabolic demands, particularly in disease states. Astrocytes demonstrate remarkable metabolic adaptability by their ability to reversibly alter the structure of their mitochondrial network through tightly regulated fusion and fission processes. This dynamic capability enables them to rapidly adjust their mitochondrial metabolism in vivo.[54]

2.4 Intracellular receptor signaling consequences of β-adrenergic receptor trafficking

In response to catecholamines, the classic G-protein-coupled receptors known as β-adrenergic receptors (βARs) are essential for controlling the responses of the heart and neurons under stress. Conventionally, one of the main ways to stop receptor signaling (also known as receptor desensitization) is through agonist-induced receptor endocytosis.[55] G-protein-coupled receptors (GPCRs) constitute the largest group of membrane receptors and serve as key targets for many widely used medications. They initiate a wide range of signaling processes, including neurotransmission, metabolism, cell growth, and immune responses.[56] According to numerous studies, adrenergic signaling-related proteins (e. g. A. Gβγ, Gαs adenylate cyclase, and βAR) often colocalize within specific microdomains, likely due to an address signal directing them to these regions. One possible area that probably has an address site is the cytoplasmic tail of βAR.[57] The regulation of these receptors, along with their interactions with scaffolding and structural proteins, tightly controls cellular trafficking and distribution. Upon receptor stimulation, this configuration is necessary for a particular cellular activity.[58] Through the Gs-adenylyl cyclase-cAMP-dependent PKA pathway, both β1- and β2-adrenergic receptors enhance cardiac contraction upon agonist stimulation.[59] Constrained to caveolae β2AR causes a two-phase response: PKA-independent initial rise in contraction rate followed by a sustained contraction rate decrease, which can be prevented by the Gi inhibitor pertussis toxin. This suggests that β2AR couples sequentially to Gs and then to Gi.[60] As a result, membrane partitioning of ion channels acting as βAR effectors has been shown in multiple labs. Caveolar membranes are connected to both Gαs and sodium channels. PKA-independent isoproterenol-induced elevation of sodium current in the heart can be functionally mediated by sodium channels found in the caveolar membrane of cardiomyocytes.[61] Pathophysiological modifications in Ca2+ signaling may result from modifications in the molecular assembly and ultrastructure of caveolae. β2AR signaling can modify L-type Ca2+ channel activity in different subcellular microdomains in cardiomyocytes according to studies employing the cell-attached patch-clamp technique.[62] A substantial body of evidence substantiates the idea that the βAR abnormalities observed in failing hearts are primarily caused by a chronic rise in circulating catecholamine levels.[63] Nevertheless, the Rockman laboratory has demonstrated that heart failure and prolonged catecholamine stimulation cause the plasma membrane βAR to be lost and receptors and their redistributed to endosomal compartments.[64]



Figure 5: Distribution of βAR. In healthy cardiac myocytes β1AR is found in the crest membrane and T-tubules while β2AR is found in the caveolae membrane and T-tubules. As the number of caveolae decreases β2AR is not confined in caveolae while β1AR is moved to endosomes in failing cardiac myocytes.

All of β2AR and only a portion of β1AR are found in caveolae, while only β1AR is found in the remaining plasma membrane. In general, caveolae exclude the great majority of the β1AR population.[65] Upon activation by an agonist, both

β1- and β2ARs initiate an increase in heart muscle contraction through the Gs-adenylyl cyclase-cAMP-dependent PKA signaling pathway as shown in **Figure 5**.[66]

2.5. Lymphocyte traffic disorders

The rough endoplasmic reticulum (RER) synthesizes proteins, which are then folded and sent to the Golgi apparatus through vesicle-mediated trafficking.[67] Once post-translational modifications are completed in the Golgi apparatus, the vesicles can follow different pathways: they may be directed to lysosomes via endosomal transport, secreted from the cells through regulated exocytosis, or integrated into the plasma membrane as proteins(constitutive transport).[68] Vesicles are transported within the cell, particularly by the coat proteins. Vesicles making their way from the cis-Golgi to the RER (via retrograde transport) are coated by COPI. Also, going from the RER to the cis-Golgi (anterograde transport) are coated by COP II, while those going from the Golgi to the lysosomes and from the plasma membrane to the lysosomes are coated by Clathrin.[69]



Figure 6: A diagram outlines various trafficking-related cellular defects affecting immune cells, classifying them by the underlying molecular pathways such as vesicle transport, cytoskeletal disruption, and autophagy anomalies.

Abnormalities of intracellular transport with a focus on lymphocytes, specifically T cells and natural killer (NK) cells. The secretory pathway is how immune cells mediate inflammation and target cell death as depicted in **Figure 6** by releasing cytokines, chemokines, and secretory lysosomal enzymes.[70]

Table 1: Pathophysiologic types of cellular trafficking disorders in lymphocytes.

Category	Condition	Genetic factors	Notes
Vesicular Trafficking	Familial Hemophagocytic Lymphohistiocytosis(FHL)	PRF1,UNC13D,STX11, STXBP2,NBAS	Immune dysregulation due to vesicular trafficking defects
Syndromic Disorders	Chediak-Higashi Syndrome	LYST,BLOC-1 subtypes	Characterized by abnormal vesicular trafficking and immune dysfunction.
	Griscelli Syndrome	RAB27A	Includes pigmentary and immune system abnormalities.
	Herman-Sky-Pudiak syndrome	AP3B1	Results in albinism and bleeding diathesis.
Lymphoproliferative Disorder	XMEN Syndrome	MAGT1, TMEM129	Associated with immune dysregulation
	COPA-Associated Vasculopathy	COPA	Autoimmune and inflammatory features
	STING Syndrome and Related Disorders	DKC1,FLII, HYOU1, JAG1 PACS1, TIC37, VIPAS39	Vasculopathy and systemic inflammation.
Autophagy Disorders	Vici Syndrom	EPG5	Results in multisystemic failure
Cytoskeletal Abnormalities	Wiskott-Aldrich Syndrome	WAS	Affects Immune system and cytoskeletal function.
	Takenouchi-Kosaki syndrome	CDC42	Involves developmental and immune defects.
Other Disorders	Immune-Related Diseases	ATP6AP1	Associated with immune dysregulation.
	Systemic lupus Erythematosus (SLE)	Multiple factors	Autoimmune condition affecting multiple organs.
	Pustular Psoriasis	Various factors	Chronic inflammatory skin condition.

Table 1 lists the membrane trafficking disorders in lymphocytes according to the Garcia-Cazoria et al. proposed mechanism. As well as the associated ailments.[71]

2.6. Altered trafficking of mucins (MUC) in benign and malignant conditions

High molecular weight O-glycoproteins known as mucins (MUC) are primarily expressed on the surface of epithelial cells.[72]The tissue-specific expressions of mucins play a vital role in immunity, cellular adhesion, differentiation, epithelial protection, lubrication, and maintaining epithelial properties.[73] Notably, MUC4 is highly overexpressed in breast and stomach cancers.[74-75] MUC1 cytoplasmic and membrane expression/localization was analyzed by Ceriani

and associates using immunohistochemistry (IHC) on 227 patients with breast cancer in 1992. They discovered that improved survival and prognosis for patients with breast cancer were associated with weak cytoplasmic intensity and a strong presence of MUC1 on the cell surface.[76] There is also a correlation between high-risk papillary thyroid carcinoma and aberrant cytoplasmic MUC1 expression.[77] It is evident from studies that cancer pathology is linked to abnormal MUC localization, depicted in **Figure 7**.[78] Investigating the mechanisms that modify MUC trafficking among various subcellular compartments is therefore crucial.[79] MUC1 can be endocytosed by macropinocytosis in addition to clathrin-mediated endocytosis, according to a different study.[80]



Figure 7: The figure illustrates the intracellular journey and abnormal compartmentalization of mucins like MUC1 in pathological conditions, highlighting how such alterations influence cancer progression.

It is possible to palmitoylate the CQCRRK sequence motif found in MUC1. MUC1's palmitoylation has been linked to the retention of the MUC1 plasma membrane. This motif is found at the intersection of the cytoplasmic tail and the TM domain. To ensure the retention of MUC1 at the apical surface, its recycling is regulated without affecting the rate of endocytosis.[81]The interactions between MUC1-CT and endocytosis-regulating proteins may be interfered with by conformational changes brought on by palmitoylation of the MUC1 cytoplasmic tail. Interestingly, this mechanism is also relevant to various receptors, ion channels, and signaling proteins.[82] It is generally accepted that advanced ovarian cancer is associated with decreased MUC16 expression. These studies collectively suggested that MUC16 may be able to modify different signaling pathways through interactions with E-cadherin, β-catenin, and/or MUC16.[83]

2.7. Vesicular trafficking, regulated by cascade activation of rab proteins

Rab is involved in the formation of extracellular vesicles. Because of their strong evolutionary conservation, Rab proteins are critical for cellular activities. Rab numbers are increasing throughout evolution as organisms get more complex: 39 in Metazoa, 62 in Vertebrates, and 66 in humans from 20 Rab in the most recent known common ancestor in six Rab supergroups.[84] Although these proteins are located in various areas of the cell, they all follow the same cycle of activation and inactivation.[85] Because of their role in the endosomal machinery, Rab proteins are the subject of much research. This makes it possible to identify which proteins should be sent to the lysosomal degradation pathway and which can be separated for recycling. The process of membrane invagination, where a section of the plasma membrane folds inward and forms an early endosome, can lead to two outcomes based on its composition. This endosome will either become a recycling endosome or transition into a late endosome. Recycling endosomes are responsible for returning proteins, such as the transferring receptor (TfR) and low-density lipoprotein receptor (LDLR), back to the cell membrane. Rab proteins play key roles in many cellular transport activities. For instance, Rab8, Rab10, and Rab14 are involved in guiding vesicles from the Golgi network to the plasma membrane.[86]



Figure 8: This diagram demonstrates the involvement of Rab proteins, particularly Rab27, in directing vesicles to the plasma membrane. It emphasizes their essential role in exosome formation, membrane docking, and cellular export processes.

A recent study revealed MVB fusing with the plasma membrane. The microscopic study revealed that MVB fusing to the plasma membrane is only positive for Rab27 which is depicted in **Figure 8**, neither Rab7a nor Arl8b, two other GTPases. As it approaches the plasma membrane, the PM MVB loses Arl8 b, which is replaced by Rab27a, allowing for fusion with the plasma membrane.[87]

Thus, Rab27a and b proteins, which are crucial for the biogenesis of EVs, would essentially decorate CD63+ MVBs fusing with the plasma membrane. As with secretory granule exocytosis. Rab27 and its effectors—in particular Rab27a—are crucial for secretions,[88] as well as when intracellular vesicles dock or tether with acceptor membranes.[89] Additionally, the amphisome biogenesis pathway involves Rab27s. They contribute to the release of tiny extracellular vesicles from the amphisomes as the autophagosome and PM fuse.[90] By rearranging the actin cytoskeleton—a process necessary for vesicular trafficking and plasma membrane distortion—Rab27a also contributes to the formation of microvesicles, which are average-size EVs, and ectosomes,

which are small EVs in the PM. According to descriptions, Rab27b plays a role in oligodendrocyte lysosomal exocytosis.

2. Discussion

Intracellular trafficking is no longer viewed as a passive logistical system but rather as a tightly regulated network integral to maintaining cellular integrity, immune balance, and neuronal communication. The pathological consequences of trafficking dysregulation span a wide range of systems. Intracellular trafficking plays a key role in regulating immune responses in the brain. In Alzheimer's disease (AD), faulty protein transport affects the accumulation and clearance of β-amyloid, worsening disease progression. Microglial dysfunction, due to impaired trafficking, also disrupts their phagocytic abilities and leads to increased neuroinflammation. This abnormal immune activity further contributes to neuronal damage.

In Parkinson's disease (PD), the disruption of vesicle transport along microtubules directly impacts dopaminergic neurons. These cells are highly reliant on trafficking machinery to maintain synaptic integrity. The buildup of α-synuclein interferes with neurotransmitter release, marking early stages of PD. Therapeutic strategies that enhance trafficking pathways could help slow disease progression. Mitochondria are essential not only for energy production but also for regulating neuronal growth and communication. The balance between mitochondrial fission and fusion enables neurons to respond to metabolic stress. Any disturbance in mitochondrial transport affects synaptic activity and is linked to several neurodevelopmental and neurodegenerative diseases.

Trafficking of β-adrenergic receptors influences heart muscle contraction. In healthy cells, these receptors localize to specific membrane regions to maintain signaling precision. However, in heart failure, chronic stimulation leads to internalization and mislocalization of receptors. Understanding this altered signaling pathway could help improve treatments for cardiovascular diseases. Lymphocyte function depends on accurate vesicle transport for cytokine release and cell movement. Mutations affecting trafficking proteins can result in immune disorders such as Chediak-Higashi syndrome or Wiskott-Aldrich syndrome. These defects impair the immune response, highlighting the importance of intracellular transport in immunity.

Abnormal trafficking of mucins, such as MUC1 and MUC16, has been observed in many cancers. Instead of being confined to the cell surface, mucins are mislocalized to the cytoplasm, which disrupts normal signaling and cell adhesion. This shift facilitates tumor growth and invasion, making mucin trafficking a potential target for cancer therapy. Rab GTPases coordinate the transport and docking of vesicles at cellular membranes. Rab27a and Rab27b, in particular, are critical for exosome release and immune granule secretion. Disruption in Rab function can impair cellular export mechanisms and is associated with both immune and neurological disorders.

3. Conclusion

Neuroinflammation's spatiotemporal dynamics require research utilizing systems theory and biology. For targeted treatments, a novel pathway-based pharmacological model is required, and biomarkers can assist in identifying significant temporal-spatial dynamics. At every stage of a neuron's life, mitochondrial activity is essential, and impaired mitochondrial transport can result in dysfunctional neurons. Our knowledge of how mitochondria function in both healthy and diseased conditions can be enhanced by additional research employing cutting-edge imaging techniques. Although the autophagy pathway may be used for therapeutic purposes, its applicability is constrained by adverse effects. Techniques that lower α-synuclein levels have been shown to improve intracellular trafficking and inhibit the spread of Parkinson's disease. Clinical trials of α-synuclein vaccines and vaccinations have demonstrated significant effectiveness in animal studies. Antibodies targeting alpha-synuclein in vitro have the potential to block neuron-to-neuron transmission via exosomes, potentially halting disease progression. Exogenous exosomes with RNA sequences that suppress the expression of α-synuclein are recommended by researchers. A key perspective on Parkinson's disease is its characterization as a disorder involving disrupted intracellular trafficking, a process critically important for dopaminergic neurons. Finding cellular signaling patterns requires the endocytic sorting of GPCRs. Pathological cardiac conditions may benefit from better treatments based on research on endomembrane G-protein activation and endosome-based signaling.

4. Acknowledgement

I would like to extend my heartfelt appreciation to each one who helped in the completion of this paper. Special thanks, in particular, go to Dr. Malavika Bhattacharya, Sudeshna Sengupta, and Rojina Khatun for their precious input and guidance, whose expertise has been indispensable in moulding this work. Finally, I am in debt to the researchers and scientists whose work laid the basis for this paper, giving me knowledge and inspiration to delve further into the complexities of intracellular trafficking and its role in disease.

5. Source of Funding

None.

6. Conflict of Interest

None.

References

1. Iovine J.C., Claypool S.M., Alder N.N. Mitochondrial compartmentalization: emerging themes in structure and function. *Trends in Biochemical Sci*, 2021;*46*(11):902–17.
2. Jackson L. Overview: Traffic at atomic resolution. *Traffic (Copenhagen, Denmark)*, 2019;*20*(12):889.
3. Aridor M., Hannan L.A. Traffic jams II: an update of diseases of intracellular transport. *Traffic (Copenhagen, Denmark)*, 2002;3(11):781–90.
4. Jiang S, Li Y, Zhang, X, Bu G, Xu H., Zhang Y.W. Trafficking regulation of proteins in Alzheimer's disease. *Molecular Neurodeg*, 2014;*9*, 6.
5. Behl, T., Kaur, I., Sehgal, A., Singh, S., Albarrati, A., Albratty, M., Najmi, A., Meraya, A. M., & Bungau, S. (2022). The road to precision medicine: Eliminating the "One Size Fits All" approach in Alzheimer's disease. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, *153*,
6. Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., Verdooner, S. R., Akman-Anderson, L., Hernández, F., Ávila, J., Emanuele, E., Valenzuela, P. L., Lucía, A., Watling M, Imbimbo B.P., Vergallo A, Lista S. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. *Frontiers in immunology*, 2020;*11*, 456.
7. Roveta, F., Bonino, L., Piella, E. M., Rainero, I., & Rubino, E. (2024). Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications. *Int J Mol Sci*, 2024;*25*(22):11941.
8. Hunn, B. H., Cragg, S. J., Bolam, J. P., Spillantini, M. G., & Wade-Martins, R. (2015). Impaired intracellular trafficking defines early Parkinson's disease. *Trends in neurosciences*, *38*(3), 178–188.
9. Hasegawa, T., Sugeno, N., Kikuchi, A., Baba, T., & Aoki, M. (2017). Membrane Trafficking Illuminates a Path to Parkinson's Disease. *The Tohoku J Experimen Med*, *242*(1):63–76.
10. Sheehan P, Yue Z. Deregulation of autophagy and vesicle trafficking in Parkinson's disease. *Neuroscience letters*, 2019;*697(1)*:59–65.
11. Rangaraju V., Lewis T.L., Hirabayashi Y., Bergami M., Motori E., Cartoni R. Pleiotropic Mitochondria: The Influence of Mitochondria on Neuronal Development and Disease. *J Neu: the official J Soc Neurosci*, 2019;*39*(42):8200–8.
12. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. *Cell*, 2006;*125*(7);1241–52.
13. Murali Mahadevan H., Hashemiaghdam A., Ashrafi G., Harbauer A.B. Mitochondria in Neuronal Health: From Energy Metabolism to Parkinson's Disease. *Advanced Biol*. *5*(9),e2100663.
14. Fu Q., Xiang Y.K. Trafficking of β-Adrenergic Receptors: Implications in Intracellular Receptor Signaling. *Progress in Mol Biol Transl Sci*, 2015;*132*,151–88.
15. Fozza, C., & Longinotti, M.R. (2010). T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications. *Advances in Hematology, 2011*.
16. Mastrogiovanni, M., Juzans, M., Alcover, A., & Di Bartolo, V. (2020). Coordinating Cytoskeleton and Molecular Traffic in T Cell Migration, Activation, and Effector Functions. *Frontiers in Cell and Developmental Biology, 8*.
17. Joshi, S., Kumar, S., Choudhury, A., Ponnusamy, M.P., & Batra, S.K. (2014). Altered Mucins (MUC) Trafficking in Benign and Malignant Conditions. *Oncotarget, 5*, 7272-84.
18. Rachagani, S., Torres, M.P., Moniaux, N., & Batra, S.K. (2009). Current status of mucins in the diagnosis and therapy of cancer. *BioFactors, 35*.
19. Haridas D, Ponnusamy M.P, Chugh S., Lakshmanan I., Seshacharyulu P., Batra S.K. MUC16: molecular analysis and its functional implications in benign and malignant conditions. *FASEB J Official Pub Feder Am Soc Experimen Biol.*, 2014;*28*(10):4183–99.
20. Joshi S., Kumar S., Choudhury A., Ponnusamy M.P., Batra, S.K. Altered Mucins (MUC) Trafficking in Benign and Malignant Conditions. *Oncotarget, 2014;5*:7272-84.
21. Menaceur C., Dusailly O., Gosselet F., Fenart L., Saint-Pol, J. (2023). Vesicular Trafficking, a Mechanism Controlled by Cascade Activation of Rab Proteins: Focus on Rab27. *Biology, 12*.
22. Catz S.D, Regulation of vesicular trafficking and leukocyte function by Rab27 GTPases and their effectors. *J Leukocyte Biol*, 2031;*94*(4):613–22.
23. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL. Neuroinflammation in Alzheimer's disease. *The Lancet. Neurology*, 2015;14(4):388–405.
24. Arranz AM, De Strooper B. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. *The Lancet. Neurol*, 2019;18(4):406–14.
25. Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, Navarro V, Nuñez-Diaz C, Sanchez-Varo, A. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. *Glia*, 2018;66(3):637–53.
26. Sarlus H, Heneka M.T. Microglia in Alzheimer's disease. *J Clin Invest*. 2017;*127*(9):3240–9.
27. Tang, Y., & Le, W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. *Molecular neurobiol.* 2016;*53*(2):1181–94.
28. Edwards F. A. (2019). A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. *Trends Neurosci*, *42*(5):310–22.
29. Venegas C, Kumar S., Franklin B.S., Dierkes T., Brinkschulte R, Tejera, D. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. *Nature*, 2017;*552*(7685):355–61.
30. Joshi P, Turola E, Ruiz A, Bergami A, Libera DD, Benussi L. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. *Cell Death Differen*, 2014;21(4):582–93.
31. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, 2017;541(7638):481–7.
32. Jensen CJ, Massie A, De Keyser J. Immune players in the CNS: the astrocyte. *J Neuroimm Pharmacol: the official J Soc Neuro Immune Pharmacol*, 2013;8(4):824–39.
33. Halassa MM, Fellin T, Takano H, Dong JH., Haydon PG. Synaptic islands defined by the territory of a single astrocyte. *J Neurosci: official J Soc Neurosci*, 2007;27(24):6473–7.
34. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. *Nature Med.*, 2003;9(4):453–7.
35. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet (London, England)*, 2009;*373*(9680):2055–66.
36. de Rijk M.C., Breteler MM., Graveland GA, Ott A., Grobbee DE, van der Meché FG. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. *Neurology*, 1995;*45*(12):2143–6.
37. Hancock W.O. Bidirectional cargo transport: moving beyond tug of war. *Nature reviews. Mol Cell Biol*, 2014;15(9):615–28.
38. Hua W., Young E.C., Fleming ML, Gelles J. Coupling of kinesin steps to ATP hydrolysis. *Nature*, 1997;*388*(6640):390–3.
39. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S., Kachergus J. Alpha-Synuclein locus triplication causes Parkinson's disease. *Sci (New York, N.Y.)*, 2003;*302*(5646):841.
40. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. *The Eur J Neurosci*. 2008;*27*(4):947–57.
41. Giehm L, Svergun D.I., Otzen D.E., Vestergaard B. (2011). Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. *Proceedings of the National Academy of Sciences of the United States of America*, 2011;108(8):3246–51.
42. Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. *Brain J Neurol*, 2014;137(5):1496–513.

43. Cramb KML, Beccano-Kelly D, Cragg SJ, Wade-Martins R. Impaired dopamine release in Parkinson's disease. *Brain: J Neurol*, 2023;146(8):3117–32.
44. Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. *Proceed Nat Acad Sci United States Am.* 2013;110(42):E4016–25.
45. Wilhelm BG, Mandad S, Truckenbrodt S, Kröhnert K, Schäfer C., Rammner B. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. *Sci (New York, N.Y.)*.2014;*344*(6187):1023-8.
46. Rangaraju V, Lewis TL, Hirabayashi Y, Bergami M, Motori E, Cartoni R. Pleiotropic Mitochondria: The Influence of Mitochondria on Neuronal Development and Disease. *J Neurosci: official J Soc Neurosci.*, 2019;*39*(42):8200–8.
47. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. *Cell*. 2006;*125*(7):1241–52.
48. Son G, Han J. Roles of mitochondria in neuronal development. *BMB Rep*, 2018;51(11):549–56.
49. Xavier JM, Rodrigues CM, Solá S. Mitochondria: Major Regulators of Neural Development. *Neurosci: a Rev J Bring Neurobiol, Neurol Psychiatry*. 2016;*22*(4):346–358.
50. Rangaraju V, Lewis TL, Hirabayashi Y, Bergami M, Motori E, Cartoni R., (2019). Pleiotropic Mitochondria: The Influence of Mitochondria on Neuronal Development and Disease. *The Journal of neuroscience: the official J Soc Neurosci*, 2019;39(42):8200–8.
51. Rangaraju V, Tom Dieck S, Schuman EM. Local translation in neuronal compartments: how local is local?. *EMBO Rep.*, 2017;18(5):693–711.
52. Chen H, Chan DC. Metabolic regulation of mitochondrial dynamics. *The J Cell Biol.*, 2016;212(4):379–87.
53. Motori E, Puyal J, Toni N, Ghanem A, Angeloni C, Malaguti M. Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance. *Cell metabolism*, 2013;18(6):844–59.
54. Fu, Q., & Xiang, Y. K. (2015). Trafficking of β-Adrenergic Receptors: Implications in Intracellular Receptor Signaling. *Progress in molecular biology and translational science*, *132*, 151–188. Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane receptors. *Nature reviews. Molecular cell biology*, *3*(9), 639–650. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. *Science (New York, N.Y.)*, *296*(5574):1821–5.
55. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nature reviews. Molecular cell biology*, 2002;*3*(9):639–50.
56. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. *Science (New York, N.Y.)*, 2002;296(5574):1821–5.
57. Hall RA. Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. *Circulation Res*, 2002;91(8):672–80.
58. Lefkowitz R.J. Seven transmembrane receptors: something old, something new. *Acta physiologica (Oxford, England)*, 2007;190(1):9–19.
59. Xiang Y, Rybin VO, Steinberg SF, Kobilka B. Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. *J Biol Chem*, 2002;*277*(37):34280–6.
60. Yarbrough TL, Lu T, Lee HC, Shibata EF. Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. *Circulation research*, 2002;90(4):443–9.
61. Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H. G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels. *Biosysph J*, 2000;*79*(5):2547–56.
62. Rockman HA, Koch WJ, Lefkowitz R.J. Seven-transmembrane-spanning receptors and heart function. *Nature*, 2002;415(6868):206–12.
63. Fu Q, Xiang YK. Trafficking of β-Adrenergic Receptors: Implications in Intracellular Receptor Signaling. *Progress Mol Biol Transla Sci*, 2051;132;151–88.
64. Xiang Y, Rybin VO, Steinberg SF, Kobilka B. Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. *J Biologi Chemi*, 2002;*277*(37):34280–6.
65. Lefkowitz RJ. Seven transmembrane receptors: something old, something new. *Acta physiologica (Oxford), England)*, 2007;*190*(1):9–19.
66. Howell GJ, Holloway ZG, Cobbold C, Monaco AP, Ponnambalam S. Cell biology of membrane trafficking in human disease. *Int Rev Cytology*, 2006;*252*:1–69.
67. Buratta S, Tancini B, Sagini K, Delo F, Chiaradia E., Urbanelli L. Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular. *Int J Mol Sci*. 2020;21(7):2576.
68. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. *Cell*, 2004;116(2):153–66.
69. Hosahalli Vasanna S, Dalal J. Traffic jam within lymphocytes: A clinician's perspective. *Front Immunol*, 2023;13:1034317.
70. García-Cazorla A, Oyarzábal A, Saudubray M, Martinelli D, Dionisi-Vici C. Genetic disorders of cellular trafficking. *Trends Gen: TIG* 2022;*38*(7):724–51.
71. Senapati S, Das S, Batra S.K. Mucin-interacting proteins: from function to therapeutics. *Trends in biochemical sciences*, 2010;*35*(4):236–45.
72. Joshi S, Kumar S, Choudhury A, Ponnusamy MP, Batra SK. Altered Mucins (MUC) trafficking in benign and malignant conditions. *Oncotarget*, 2014;5(17):7272–84.
73. Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, Chakraborty S, Jain M, Pai P. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. *PloS one*, 2013;*8*(2):e54455.
74. Senapati S, Chaturvedi P, Sharma P, Venkatraman G, Meza JL, El-Rifai W. Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. *Brit J Cancer*, 2008;*99*(6):949–56.
75. Ceriani, R. L., Chan, C. M., Baratta, F. S., Ozzello, L., DeRosa, C. M., & Habif, D. V. (1992). Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. *International journal of cancer*, *51*(3):343–354.
76. Bièche I, Ruffet E, Zweibaum A, Vildé F, Lidereau R, Franc B. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. *Thyroid: official J Ame Thyroid Assoc.*, 1997;*7*(5):725–31.
77. Joshi S, Kumar S, Choudhury A, Ponnusamy MP, Batra SK. Altered Mucins (MUC) trafficking in benign and malignant conditions. *Oncotarget*, 2014;*5*(17):7272–84.
78. Joshi S, Kumar S, Choudhury A, Ponnusamy MP, Batra SK. Altered Mucins (MUC) trafficking in benign and malignant conditions. *Oncotarget*, 2014;*5*(17):7272-84.
79. Liu X, Yuan Z, Chung M. MUC1 intra-cellular trafficking is clathrin, dynamin, and rab5 dependent. *Biochem Biophys Res Commun*, 2008;376(4):688–93.
80. Kinlough CL, McMahan RJ, Poland PA., Bruns JB., Harkleroad KL, Stremple RJ. Recycling of MUC1 is dependent on its palmitoylation. *J Biol Chem*, 2006;281(17):12112–22.
81. Aicart-Ramos C, Valero RA, Rodriguez-Crespo I. Protein palmitoylation and subcellular trafficking. *Biochimica et biophysica acta*, 2011;1808(12):2981–94.
82. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther, S. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. *Gynecol Oncol*, 2007;104(3):508–15.
83. Menaceur C, Dusailly O, Gosselet F, Fenart L, Saint-Pol J. Vesicular Trafficking, a Mechanism Controlled by Cascade Activation of Rab Proteins: Focus on Rab27. *Biology*. 2023;12(12):1530.
84. Menaceur C, Dusailly O, Gosselet F, Fenart L, Saint-Pol J. Vesicular Trafficking, a Mechanism Controlled by Cascade Activation of Rab Proteins: Focus on Rab. *Biol*. 2023;*12*(12):1530.

85. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. *J Cell Biol*, 1983;*97*(2);329–39.
86. Verweij FJ, Bebelman MP, George AE, Couty M, Bécot A, Palmulli R. ER membrane contact sites support endosomal small GTPase conversion for exosome secretion. *J Cell Biol*, 2022;*221*(12), e202112032.
87. Fukuda M. Rab27 and its effectors in secretory granule exocytosis: a novel docking machinery composed of a Rab27.effector complex. *Biochem Soc Trans*, 2006;*34*(5):691–5.
88. Tsuboi T, Fukuda M. Rab3A and Rab27A cooperatively regulate the docking step of dense-core vesicle exocytosi in PC12 cells. *J Cell Sci*, 2006;119(11):2196–203.
89. Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman L. Reassessment of Exosome Composition. *Cell*, 2019;177(2):428–45.
90. Shen YT, Gu Y, Su WF, Zhong JF, Jin ZH, Gu XS. Rab27b is Involved in Lysosomal Exocytosis and Proteolipid Protein Trafficking in Oligodendrocytes. *Neurosc Bull.* 2016;32(4):331–40.

Cite this article: Paria A, Khatun R, Sengupta S, Bhattacharya M. Intracellular trafficking in pathophysiological conditions. *Indian J Clin Anat Physiol*. 2025;12(2):42-51.